Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.


Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (Nmdar) Or Anti-Leucine-Rich Glioma-Inactivated 1 (Lgi1) Encephalitis

therapist assisting elderly woman
Age: 12+ years old
Sex at Birth: All
Type: Interventional Study
Condition: Autoimmune Encephalitis
Healthy Participants: No
Location: UH Cleveland Medical Center

Learn More About This Research Study

For more information, please contact study coordinator, Madelyn Pierce Moberg at 216-286-6564 and leave a message or complete the online form below.

Study Purpose

The purpose of this study is to assess the effects, good or bad, of an investigational treatment in participants with autoimmune encephalitis. In the study, half of the participants will receive an investigational treatment, and the other half will receive a placebo. This investigational treatment is in addition to the continuation or completion of standard therapy for autoimmune encephalitis. The effects will be compared between those who receive investigational treatment and those who receive placebo. A placebo looks exactly like the study drug but has no active ingredient.

Who Can Participate

Participants 12 years old and older with onset of autoimmune encephalitis symptoms within the last 9 months may be eligible for this study.

Request More Information

To learn more about this study, please fill out the form below to request more information.

I'm not a robot